Aberrant methylation underlies insulin gene expression in human insulinoma.
Esra KarakoseHuan WangWilliam InabnetRajesh V ThakkerSteven LibuttiGustavo Fernandez-RanvierHyunsuk SuhMark StevensonYayoi KinoshitaMichael DonovanYevgeniy AntipinYan LiXiaoxiao LiuFulai JinPeng WangAndrew V UzilovCarmen A ArgmannEric E SchadtAndrew F StewartDonald K ScottLuca LambertiniPublished in: Nature communications (2020)
Human insulinomas are rare, benign, slowly proliferating, insulin-producing beta cell tumors that provide a molecular "recipe" or "roadmap" for pathways that control human beta cell regeneration. An earlier study revealed abnormal methylation in the imprinted p15.5-p15.4 region of chromosome 11, known to be abnormally methylated in another disorder of expanded beta cell mass and function: the focal variant of congenital hyperinsulinism. Here, we compare deep DNA methylome sequencing on 19 human insulinomas, and five sets of normal beta cells. We find a remarkably consistent, abnormal methylation pattern in insulinomas. The findings suggest that abnormal insulin (INS) promoter methylation and altered transcription factor expression create alternative drivers of INS expression, replacing canonical PDX1-driven beta cell specification with a pathological, looping, distal enhancer-based form of transcriptional regulation. Finally, NFaT transcription factors, rather than the canonical PDX1 enhancer complex, are predicted to drive INS transactivation.
Keyphrases
- transcription factor
- single cell
- endothelial cells
- gene expression
- dna methylation
- type diabetes
- cell therapy
- stem cells
- induced pluripotent stem cells
- genome wide
- poor prognosis
- pluripotent stem cells
- binding protein
- induced apoptosis
- signaling pathway
- cell death
- mass spectrometry
- high resolution
- adipose tissue
- immune response
- oxidative stress
- copy number
- cell proliferation
- endoplasmic reticulum stress
- genome wide identification